The Wall Street Journal offers an in-depth look at Michael Jaharis, a noted biotech entrepreneur who recently sold Kos Pharmaceuticals to Abbott for $4.2 billion. Jaharis has launched Vatera Capital, wagering he can still pick a hot prospect. He's already invested in Aveo's fourth round and now he's looking at "dozens" of other plays to put his money to work. He should be well funded: Jaharis owned more than half of Kos when it was sold.
- read the profile from the Wall Street Journal (sub. req.)